"10.1371_journal.pone.0013474","plos one","2010-10-18T00:00:00Z","Ines Herrmann; Patrick A Baeuerle; Matthias Friedrich; Alexander Murr; Susanne Filusch; Dominik Rüttinger; Mariam W Majdoub; Sherven Sharma; Peter Kufer; Tobias Raum; Markus Münz","Micromet AG, Munich, Germany; Micromet, Inc., Bethesda, Maryland, United States of America; Celprogen Inc, San Pedro, California, United States of America; Department of Medicine, University of California Los Angeles, Los Angeles, California, United States of America; Molecular Gene Medicine Laboratory, Greater Los Angeles Healthcare System, Los Angeles, California, United States of America","Conceived and designed the experiments: TR MM. Performed the experiments: IH AM. Analyzed the data: IH PB TR MM. Contributed reagents/materials/analysis tools: MF SF DR MWM SS PK. Wrote the paper: PB MM.","IH, PAB, MF, AM, SF, DR, PK, TR and MM are employees of Micromet, Inc., and have equity positions in the company. Micromet is focused on the development of BiTE antibodies for the treatment of malignant diseases. MWM is an employee of Celprogen, a biotechnology company developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes and neurology. SS is employed by University of California Los Angeles Lung Cancer Research Program, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, Molecular Gene Medicine Laboratory, Veterans Affairs, Greater Los Angeles Healthcare System, Los Angeles, California and is a collaborator of Celprogen. This does not alter the authors' adherence to all the PLoS ONE policies on sharing data and materials. The present study has not been used for a new patent filing.","2010","10","Ines Herrmann","IH",11,TRUE,2,2,4,2,TRUE,TRUE,FALSE,0,NA,FALSE
